Inhibrx Biosciences Announces Director and Officer Changes
Ticker: INBX · Form: 8-K · Filed: Apr 1, 2025 · CIK: 2007919
| Field | Detail |
|---|---|
| Company | Inhibrx Biosciences, Inc. (INBX) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, governance
Related Tickers: INHX
TL;DR
Inhibrx Biosciences filed an 8-K on 3/31/25 for director/officer changes & comp. Watch for leadership shifts.
AI Summary
On March 31, 2025, Inhibrx Biosciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potentially new incentive structures for key personnel within the company.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts, potential future performance, or changes in governance that investors should monitor.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensation adjustments, can indicate internal shifts that may impact the company's future direction and performance.
Key Players & Entities
- Inhibrx Biosciences, Inc. (company) — Registrant
- March 31, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 11025 N. Torrey Pines Road, Suite 140 (address) — Principal Executive Offices
- La Jolla, CA (location) — Principal Executive Offices City and State
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific names and details of these changes are not provided in the initial summary of the 8-K.
What are the key aspects of the compensatory arrangements mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item information, suggesting updates or new details regarding executive pay, but specific details are not in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on March 31, 2025.
What is the principal executive office address for Inhibrx Biosciences, Inc.?
The principal executive office address is 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA 92037.
What is the SIC code for Inhibrx Biosciences, Inc.?
The Standard Industrial Classification (SIC) code for Inhibrx Biosciences, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 1, 2025 regarding Inhibrx Biosciences, Inc. (INBX).